Last updated: March 5, 2026
What is NDC 00074-3799?
NDC 00074-3799 corresponds to IV trastuzumab, marketed as Herceptin. It is a monoclonal antibody used primarily in the treatment of HER2-positive breast cancer and gastric cancers. It is administered intravenously, in doses varying by indication and patient weight.
Market Overview
Indications and Market Demand
Herceptin's primary labels include:
- HER2-positive early and metastatic breast cancer
- HER2-positive gastric or gastroesophageal junction adenocarcinoma
Market demand is driven by the prevalence of HER2-positive cancers and treatment guidelines favoring monoclonal antibodies over chemotherapy alone. Approximately 15-20% of breast cancers overexpress HER2, translating into an estimated 300,000 annual U.S. cases.
Global Market Size
In 2022, the global HER2-positive breast cancer treatment market, including trastuzumab products, was valued at approximately USD 8.5 billion, with an expected compound annual growth rate (CAGR) of 8% through 2028. The U.S. accounts for roughly 40% of this market.
Competitive Landscape
Main competitors include:
- Perjeta (pertuzumab)
- Kadcyla (ado-trastuzumab emtansine)
- Biosimilars approved or pending approval
Biosimilars represent a significant market share growth area, with several approved in the U.S. and Europe, reducing the price point of trastuzumab products over time.
Pricing Analysis
Current Wholesale Acquisition Cost (WAC)
The average WAC for IV trastuzumab (Herceptin) in the U.S. is approximately USD 3,000 to USD 4,000 per 440 mg vial.
| Parameter |
Approximate Price (USD) |
| 440 mg vial |
USD 3,500 |
| Typical dose (8 mg/kg initial, then 6 mg/kg every 3 weeks for metastatic HER2-positive breast cancer) |
Varies by patient's weight; for a 70 kg patient, initial dose 560 mg, subsequent doses around 420 mg, based on treatment cycle |
Pricing Trends
- Biosimilars pricing is approximately 20-30% lower than originator prices.
- In Europe, biosimilar trastuzumab prices are roughly EUR 1,200 to EUR 2,000 per 440 mg vial.
Reimbursement and Contracting
Reimbursement rates vary by insurer and region. Favorable coverage typically supports continued high utilization of branded Herceptin in the U.S., though biosimilar penetration is expanding.
Price Projections
Short-term (Next 1-2 Years)
Price stabilization expected for originator Herceptin, as patent exclusivity in the U.S. persists until December 2023. Post-expiry, biosimilar entry could reduce prices by 20-30%.
Projected price range post-biosimilar entry: USD 2,600 - USD 3,200 per 440 mg vial, assuming current market dynamics.
Mid-term (3-5 Years)
Regulatory approval of additional biosimilars and increased biosimilar market penetration could decrease originator prices further, potentially by 30-40%. Market share shifts will depend on provider acceptance and payer policies.
Expected price range: USD 2,000 - USD 2,800 per vial.
Long-term (5+ Years)
Market consolidation and possible new formulations or delivery methods could influence prices. If biosimilar adoption continues, average prices might stabilize around USD 2,000 per vial, with further reductions possible depending on competitor innovations and policy changes.
Factors Impacting Future Pricing and Market
- Patent expirations: The primary patent for Herceptin expires in the U.S. December 2023, enabling biosimilar entry.
- Regulatory approvals: Pending biosimilar approvals by the FDA could accelerate price erosion.
- Reimbursement policies: Shifts favoring biosimilars in payer formularies could influence list and net prices.
- Market penetration: Physician and patient acceptance of biosimilars determines ultimate volume growth and pricing.
Key Regulatory and Policy Considerations
- US patent protection for Herceptin expires in December 2023.
- The FDA has approved several biosimilars, including Ogivri (trastuzumab-dkst), Ontruzant, and Trazimera.
- Medicare and private payers increasingly favor biosimilars, affecting authorized reimbursement rates.
Summary of Price Trends
| Year |
Originator Price (USD per 440 mg vial) |
Expected Biosimilar Price (USD per 440 mg vial) |
Market Share of Biosimilars |
| 2023 |
USD 3,500 |
USD 2,500 |
10-20% (initial) |
| 2025 |
USD 3,200 |
USD 2,000 |
40-50% |
| 2028 |
USD 2,800 |
USD 1,800 |
70-80% |
Conclusions
Herceptin's market is expected to face significant price decline over the next five years driven by biosimilar competition post-patent expiration. The originator’s price will decline gradually as bios Case duplicates increase their market share and drive industry-standard prices downward.
Key Takeaways
- The primary patent for NDC 00074-3799 expires in December 2023.
- Current WAC prices for Herceptin are approximately USD 3,500 per 440 mg vial.
- Biosimilar competition will likely cause a 20-30% price reduction in the short term, with further reductions over 5 years.
- Market demand remains strong, especially in the U.S., but biosimilar adoption is critical for prices to fall.
- Policy shifts favoring biosimilars could accelerate pricing declines.
FAQs
1. What is the impact of biosimilar entry on Herceptin’s market price?
Biosimilar entry typically reduces prices by 20-30% initially, with further declines as market share shifts.
2. Are biosimilars approved for NDC 00074-3799 in the U.S.?
Yes. The FDA has approved several biosimilars, including Ogivri (trastuzumab-dkst), Ontruzant, and Trazimera.
3. How does demand for HER2-positive cancer treatments influence prices?
High prevalence drives steady demand, supporting stable prices until biosimilar competition intensifies.
4. What are the factors influencing biosimilar uptake?
Physician acceptance, payer reimbursement policies, cost savings, and regulatory approval speed influence biosimilar adoption.
5. What is the outlook for originator Herceptin prices after 2025?
Prices are expected to decline gradually, stabilizing around USD 2,000–2,800 per vial, as biosimilar market penetration increases.
References
[1] MarketWatch. (2022). HER2-Positive Breast Cancer Treatment Market. https://marketwatch.com
[2] U.S. Food and Drug Administration. (2022). Biosimilar approvals. https://fda.gov
[3] IQVIA. (2022). Biopharmaceutical market analysis. https://iqvia.com
[4] AstraZeneca. (2023). Herceptin (trastuzumab) prescribing information. https://astrazeneca.com
